These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 29659732)

  • 1. Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna.
    Tobudic S; Forstner C; Burgmann H; Lagler H; Ramharter M; Steininger C; Vossen MG; Winkler S; Thalhammer F
    Clin Infect Dis; 2018 Aug; 67(5):795-798. PubMed ID: 29659732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dalbavancin for infective endocarditis: a single centre experience.
    Durante-Mangoni E; Boccia F; Ursi MP; Karruli A; Andini R; Galdo M; Zampino R
    J Chemother; 2021 Jul; 33(4):256-262. PubMed ID: 33073724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dalbavancin as long-term suppressive therapy for patients with Gram-positive bacteremia due to an intravascular source-a series of four cases.
    Hitzenbichler F; Mohr A; Camboni D; Simon M; Salzberger B; Hanses F
    Infection; 2021 Feb; 49(1):181-186. PubMed ID: 32965641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci.
    Hidalgo-Tenorio C; Vinuesa D; Plata A; Martin Dávila P; Iftimie S; Sequera S; Loeches B; Lopez-Cortés LE; Fariñas MC; Fernández-Roldan C; Javier-Martinez R; Muñoz P; Arenas-Miras MDM; Martínez-Marcos FJ; Miró JM; Herrero C; Bereciartua E; De Jesus SE; Pasquau J
    Ann Clin Microbiol Antimicrob; 2019 Oct; 18(1):30. PubMed ID: 31629409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections.
    Wunsch S; Krause R; Valentin T; Prattes J; Janata O; Lenger A; Bellmann-Weiler R; Weiss G; Zollner-Schwetz I
    Int J Infect Dis; 2019 Apr; 81():210-214. PubMed ID: 30794940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection.
    Tobudic S; Forstner C; Burgmann H; Lagler H; Steininger C; Traby L; Vossen MG; Winkler S; Thalhammer F
    Infection; 2019 Dec; 47(6):1013-1020. PubMed ID: 31520397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dalbavancin as sequential therapy for infective endocarditis due to Gram-positive organisms: a review.
    Fazili T; Bansal E; Garner D; Gomez M; Stornelli N
    Int J Antimicrob Agents; 2023 Apr; 61(4):106749. PubMed ID: 36758775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Peptostreptococcus micros endocarditis with teicoplanin.
    Wenisch C; Wiesinger E; Werkgartner T; Makristathis A; Graninger W
    Clin Infect Dis; 1995 Aug; 21(2):446-7. PubMed ID: 8562764
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections.
    Veve MP; Patel N; Smith ZA; Yeager SD; Wright LR; Shorman MA
    Int J Antimicrob Agents; 2020 Dec; 56(6):106210. PubMed ID: 33223119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of methicillin-sensitive Staphylococcus aureus tricuspid-valve endocarditis with dalbavancin as an outpatient in a person who injects drugs: A case report.
    Hakim A; Braun H; Thornton D; Strymish J
    Int J Infect Dis; 2020 Feb; 91():202-205. PubMed ID: 31841726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin.
    Steele JM; Seabury RW; Hale CM; Mogle BT
    J Clin Pharm Ther; 2018 Feb; 43(1):101-103. PubMed ID: 28628223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dalbavancin for the management of gram-positive osteomyelitis: Effectiveness and potential utility.
    Almangour TA; Perry GK; Terriff CM; Alhifany AA; Kaye KS
    Diagn Microbiol Infect Dis; 2019 Mar; 93(3):213-218. PubMed ID: 30396697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dalbavancin is a novel antimicrobial against Gram-positive pathogens: clinical experience beyond labelled indications.
    Núñez-Núñez M; Casas-Hidalgo I; García-Fumero R; Vallejo-Rodríguez I; Anguita-Santos F; Hernández-Quero J; Cabeza-Barrera J; Ruiz-Sancho A
    Eur J Hosp Pharm; 2020 Sep; 27(5):310-312. PubMed ID: 32839266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infective endocarditis and glycopeptides.
    Pittet D; Harding I
    J Infect; 1998 Sep; 37(2):127-35. PubMed ID: 9821086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of teicoplanin in the treatment of gram-positive bacterial intravascular infections.
    Livornese LL; Gold M; Johnson CC; Measley R; Kaye D; Korzeniowski O; Walsh ML; Samel C; Hessen M; Levison ME
    J Antimicrob Chemother; 1993 Jan; 31(1):188-91. PubMed ID: 8444670
    [No Abstract]   [Full Text] [Related]  

  • 17. Dalbavancin use in an academic medical centre and associated cost savings.
    Streifel AC; Sikka MK; Bowen CD; Lewis JS
    Int J Antimicrob Agents; 2019 Nov; 54(5):652-654. PubMed ID: 31398481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dalbavancin in clinical practice: a particular place for the elderly?
    Wackenheim C; Le Maréchal M; Pluchart H; Gavazzi G; Blanc M; Caspar Y; Pavese P;
    Eur J Clin Microbiol Infect Dis; 2022 Jun; 41(6):977-979. PubMed ID: 35471751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dalbavancin and telavancin in the treatment of infective endocarditis: a literature review.
    Lampejo T
    Int J Antimicrob Agents; 2020 Sep; 56(3):106072. PubMed ID: 32629114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs.
    Gatti M; Andreoni M; Pea F; Viale P
    Drug Des Devel Ther; 2021; 15():3349-3378. PubMed ID: 34376971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.